- Conditions
- Atopic Dermatitis
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 9,381
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
- Drug · Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Glendale, California • Loma Linda, California • Oakland, California + 49 more
- Conditions
- Moderate to Severe Chronic, Non-malignant Pain
- Interventions
- Hydrocodone/Acetaminophen on Extended Release
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 76
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 60 more
- Conditions
- Influenza, Human
- Interventions
- mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 54,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 161
- States / cities
- Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more
- Conditions
- Alopecia
- Interventions
- Setipiprant, Placebo, Finasteride
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 18
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more
- Conditions
- Diabetic Macular Edema
- Interventions
- nepafenac 0.1% drops, Nepafenac Vehicle
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more
- Conditions
- Ischemic Stroke
- Interventions
- TS23
- Biological
- Lead sponsor
- Translational Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Kansas City, Missouri • Portland, Oregon
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK523338
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Fresno, California • Wheat Ridge, Colorado + 38 more
- Conditions
- Inflammation, Psoriasis
- Interventions
- anti-IL-20, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Skokie, Illinois + 11 more
- Conditions
- Psoriasis
- Interventions
- Apremilast, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 23 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Inhaled human insulin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 29
- States / cities
- Burlingame, California • Irvine, California • Newport Beach, California + 26 more
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Bremelanotide, Placebo
- Drug · Other
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more
- Conditions
- Influenza, Healthy
- Interventions
- Bivalent influenza vaccine, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Stockbridge, Georgia • Portland, Oregon
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA, TEZ/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Interventions
- Tolebrutinib, Placebo, Teriflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
- Conditions
- Hemophilia A
- Interventions
- rFVIIIFc
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 0 Years and older · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 17 more
- Conditions
- Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 507
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 345 more
- Conditions
- Asthma
- Interventions
- NSI-8226, Placebo
- Biological
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Peoria, Arizona • Encinitas, California + 60 more
- Conditions
- Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric
- Interventions
- Phenoptin
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- ABBV-552, Placebo for ABBV-552
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more